CARMAT Hosts Successful Inaugural “Aeson® European User Meeting” to Advance Deployment of Artificial Heart.
CARMAT, the designer and developer of the Aeson® artificial heart, successfully held its first “Aeson® European User Meeting” on November 21 and 22, 2024, in Chantilly, near Paris. The event attracted over 100 healthcare professionals from 41 hospitals across 10 countries, highlighting significant interest in the artificial heart among the medical community.
The meeting featured cardiologists, surgeons, anesthetists, intensivists, nurses, and specialized distributors from countries including France, Germany, Italy, Spain, Poland, the Netherlands, Serbia, Slovenia, Macedonia, and Israel. Participants expressed their intent to either introduce or expand the use of Aeson® in their clinical practices.
Dr. Piet Jansen, Medical Director of CARMAT, opened the forum with a summary of clinical experiences and results from using Aeson®.
Following this presentation, various thematic sessions allowed experienced physicians to share insights with their peers who have not yet implanted the device.
Key discussion topics included:
Patient Selection and Case Studies: Attendees reviewed numerous real-life cases demonstrating Aeson®’s effectiveness across diverse patient profiles, including those previously supported by ECMO (extracorporeal membrane oxygenation) before implantation.
Anatomical Fit and Recovery: Discussions confirmed that most patients experienced a high degree of anatomical fit with the device and rapid recovery. On average, patients were discharged from the hospital 56 days post-implantation and could proceed to heart transplantation under optimal conditions.
Surgical Techniques: Participants received detailed feedback on critical steps involved in both implantation and explantation procedures to better manage surgical specifics.
Patient Management: Several sessions focused on comprehensive strategies for managing patients psychologically, physically, and through medication before, during, and after implantation.
Stéphane Piat, CEO of CARMAT, expressed his satisfaction with the meeting’s success. He emphasized the quality of discussions and enthusiasm surrounding the Aeson® heart as indicators of its growing acceptance in clinical settings. Piat noted that insights shared during the meeting reflect a genuine demand for this therapy among a wide range of patients.
This inaugural user meeting marks a significant step forward in promoting CARMAT’s Aeson® artificial heart as a viable therapeutic option for individuals suffering from advanced biventricular heart failure.
Related topics:
- American Heart Association Launches Initiative to Teach Lifesaving CPR And AED Skills in Rural Alaska
- Bayer Secures Rights to Cytokinetics’ Heart Drug for Japan
- NCH Rooney Heart Institute Receives $5 Million Donation to Enhance Cardiac Services